Biotech Stocks Rally: REPL Progresses, SNSE Awaits Phase 2 Data, IMRX Surges, CCCC in Focus

Biotechnology shares posted broad gains on June 1, 2026, fueled by developmental catalysts. Replimune Group (REPL) climbed 12% after the company confirmed its lead oncolytic immunotherapy program remains on schedule for a regulatory filing in the second half of 2026. Sensei Biotherapeutics (SNSE) advanced 8% as traders accumulated shares ahead of a Phase 2 data readout for its solid tumor candidate expected in July. Immuneering Corporation (IMRX) soared 22% following positive interim results from a pancreatic cancer study. C4 Therapeutics (CCCC) gained 5%, drawing interest amid speculation of a pending collaboration deal.